Sign in
Taking people in United KingdomNo phase

Testing minocycline, an anti-inflammatory antibiotic, in adults with obesity and depression

Tests minocycline, an anti-inflammatory medicine, in adults with obesity and depression.

Key facts

Who runs it
King's College London
Where
London, United KingdomSee the site
Trial code
Registry title
Comorbid Obesity and Depression With an Anti-inflammatory Medication
Status
Recruiting
People taking part
35 people, planned
Started
1 Oct 2024
Expected to end
1 Sept 2027
Type of study
Interventional
Treatments tested
  • Minocycline 200mg
Record updated
14 November 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults aged 18 to 65 with depression that has not responded to antidepressants and a raised CRP blood level. They would add minocycline to their current antidepressant.

Age
18 to 65 years
Sex
All sexes
Disease stage
Treatment-resistant depression: no response to the current antidepressant after at least 6 weeks and to at least one other earlier antidepressant.
Earlier treatment
Must be taking an antidepressant they tolerate, with no plan to change it during the trial. Cannot have taken any tetracycline in the last month.
Biomarker or test result
CRP above 3mg/L at screening.

Main reasons for not taking part

  • Active suicidal thoughts
  • Psychotic disorder, bipolar disorder, obsessive-compulsive disorder or post-traumatic stress disorder as the main diagnosis
  • Acute infection or autoimmune disorder
  • Taking an antibiotic, immunosuppressive medicine, warfarin, lithium or retinoids
  • Pregnant or breastfeeding

The registry criteria, word for word

Show all 23 criteriaShow less

Who can take part

  • Sufficient communication skills to understand the intervention and complete the assessments
  • Able to give informed consent
  • Treatment resistant depressed (i.e., non-responders to current antidepressant treatment, for at least 6-weeks AND at least one other previous antidepressant)
  • Tolerant to the current antidepressant
  • Able to undergo 2 MRI scans
  • Accepting augmentation with minocycline
  • CRP >3mg/L at screening
  • No plans to change current therapy for the duration of participation

Who cannot take part

  • Currently taking any antibiotic, immunosuppressive medication, or warfarin
  • Currently taking Lithium or retinoids (Acitretin, Alitretinoin, Isotretinoin)
  • [OPTIONAL - if not met, cannot undergo the MRI] Has any metal implants in their body such as pacemakers, dental fillings, IUD device (if applicable), or had any accidents where metal fragments might have entered the body or eye
  • Current primary diagnosis of psychotic disorder, bipolar disorder, obsessive-compulsive disorder, or post-traumatic stress disorder
  • Have an acute infection or an autoimmune disorder, because of both the rare but described association between minocycline and systemic lupus erythematosus, and the potential confounder effects of these conditions on immune biomarkers
  • Alcohol misuse disorder or drug addiction
  • Neurological disorders (Parkinson's, Alzheimer's)
  • Active suicidal ideation
  • Current serious cardiovascular problems
  • Have acne or psoriasis
  • Taken any tetracycline within the last month
  • Refuse that we contact their GP to inform them about their participation
  • Pregnant or breastfeeding
  • Have a positive pregnancy test before starting the study/are unwilling to take a pregnancy test and are unwilling to agree to use an acceptable form of contraceptive throughout the study period (e.g., condoms, intrauterine device (IUD)/intrauterine system (IUS), injection, patch, ring). Female participants who use combined oral contraceptives as their main form of birth control will need to use an additional barrier method for the duration of treatment and for 7 days following completion of treatment
  • Are currently participating in another Clinical Trial of Investigational Medicinal Product (CTIMP)

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 65 years old?

Where in United Kingdom

  • King's College LondonLondon, United KingdomContact: Melisa KoseTaking people

About the trial

What the trial wants to find out

Research suggests that only a subset of individuals with major depressive disorder (MDD) may benefit from anti-inflammatory treatments: those who have C-reactive protein (CRP) ≥3 mg/L, a commonly used threshold for "low-grade" inflammation. The emerging link between metabolic and immune abnormalities in MDD suggests that individuals with comorbid obesity and MDD are a subset of people who could particularly benefit from anti-inflammatory treatment. The coexistence of obesity and MDD has been shown to amplify the risk of clinically elevated CRP levels (≥3mg/L). Therefore, people with comorbid obesity, MDD, and CRP ≥3mg/L could be an ideal target population in future randomised clinical trials (RCTs). However, investigation into the feasibility and acceptability of inflammation-targeting treatment in this population is needed first.

Read full original descriptionShow less

Meta-analyses identify minocycline (a tetracycline antibiotic that can cross the blood-brain barrier) as one of the most effective inflammation-targeting medications with antidepressant effects. Minocycline can safely be used long-term at dosages of up to 200mg per day and has low tendency to lead to antibiotic resistance. A pilot RCT of minocycline found a large effect size (Cohen's d=0.98, p<0.001) for the reduction of MDD symptoms compared with placebo. This effect size was even larger (Cohen's d=1.5, p<0.005) in another RCT using minocycline when considering only participants with CRP ≥3mg/L.

One mechanism through which minocycline could ameliorate MDD symptoms appears to involve the activation of indoleamine 2,3-dioxygenase (IDO), which leads to an increase in the expression and function of the serotonin transporter. Studies exploring this anti-inflammatory effect in MDD demonstrate that minocycline indeed can inhibit IDO.

Another pathway through which minocycline could ameliorate MDD symptoms is through the reduction of inflammation at the central level. Minocycline has been shown to reduce microglia activation in preclinical models. Previous literature reports an impact of neuroinflammation on white matter microstructure and brain structure in patients with MDD and in individuals with obesity. Minocycline's effect on white matter structure and myelination has not yet been investigated in humans in vivo. Investigating whether neuroimaging biomarker candidates associated with neuroinflammation could be detected in this study design is needed.

The group in the trial

  • Comorbid depression and obesityTreatment being tested

    Participants with comorbid major depressive disorder (MDD) and obesity (BMI≥30 kg/m2) and c-reactive protein (CRP) levels ≥3mg/L at screening.

    Treatment: Minocycline 200mg

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Feasibility Study in Comorbid Obesity and Treatment-Resistant Depression Using Minocycline as Adjunctive Treatment (CODA)
Plain-language title
Testing minocycline, an anti-inflammatory antibiotic, in adults with obesity and depressionGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT06537921, who can take part
Record updated
14 November 2025